The Pharma Data

SEPTEMBER 7, 2021

KEYTRUDA plus 5-FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; KEYTRUDA plus 5-FU and cisplatin reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.55-0.76]; 0.86]; p<0.0001). The median OS was 12.4 months (95% CI, 10.5-14.0) months (95% CI, 8.8-10.8) 0.76]; p<0.0001).

HR 52

HR Packaging Packaging Trials 52

The Pharma Data

AUGUST 30, 2021

KEYTRUDA in combination with chemotherapy (pac, nab-paclitaxel or gem/carbo) reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.49, 0.86]; p=0.0012), with a median PFS of 9.7 months (95% CI, 7.6-11.3) months (95% CI, 5.3-7.5), 7.5), versus the same chemotherapy regimens alone in these patients. months [95% CI, 5.4-32.4]

Hormones 52

Hormones HR Trials Protein 52

pharmaphorum

JUNE 17, 2022

Developed by Pfizer, Paxlovid was granted emergency use authorization (EUA) to treat COVID-19 patients based on the EPIC-HR study which showed it reduced the risk of hospitalization or death by almost 90 percent. Paxlovid consists of two different drugs, nirmatrelvir 150mg tablets co-packaged with ritonavir 100mg tablets.

Drugs 105

Drugs Clinical Trials Clinical Trials HR 105

Pfizer

AUGUST 15, 2022

One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. PAXLOVID is generally administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice-daily for five days.

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

Pfizer

DECEMBER 20, 2022

One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. PAXLOVID is generally administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice-daily for five days.

Drugs 69

Drugs Licensing Licensing Containment 69

The Pharma Data

JUNE 18, 2021

months; hazard ratio [HR] 0.33 [95% CI 0.25-0.45]); with chlorambucil in combination with obinutuzumab (Obi-Clb; HR 0.85, 95% CI [0.54-1.35]; 7 VENCLEXTA (venetoclax) [Package Insert]. After a median follow-up of more than four years (52.4 0.45]); results are descriptive. with Ven-Obi versus 83.1% 1.35]; P=0.49). AbbVie Inc.

Medicine 40

Medicine HR Trials Production 40

Pfizer

DECEMBER 13, 2022

One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. PAXLOVID is generally administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice-daily for five days.

Drugs 110

Drugs Licensing Licensing Production 110

The Pharma Data

MARCH 20, 2021

The inactivated virus samples were digested with trypsin and analyzed on a high resolution Orbitrap Eclipse mass spectrometer interfaced with an RSLCnano system using a 3 hr gradient. SARS-CoV-2 nucleocapsid is highly expressed during infection ( 22 ) and a potential target for viral detection by mass spectrometry.

Protein 52

Protein Antibody Development RNA 52

The Pharma Data

DECEMBER 29, 2020

one-sided), as seronegative patients treated with the antibody cocktail had a lower risk of death or receiving mechanical ventilation (HR: 0.78; 80% CI: 0.51-1.2). The results passed the futility analysis (p<0.3 At day 5, the relative reduction compared to placebo was -1.1 log 10 copies/mL (nominal p=0.002 for combined doses).

Antibody 52

Antibody Trials Production Clinical Trials 52

Pfizer

JANUARY 27, 2023

One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. The dose for patients with moderate renal impairment (eGFR ≥30 to For more information, please visit www.PAXLOVID.com.

Marketing 75

Marketing Production Drugs Licensing 75

XTalks

AUGUST 2, 2023

2) Paxlovid (nirmatrelvir/ritonavir) Paxlovid is a dual-packaged oral medication for the treatment of COVID-19. 5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. for a 2-pen package (0.6

Sales 96

Sales Manufacturing FDA Approval Life Science 96

The Pharma Data

JUNE 18, 2021

The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent review committee (IRC) with a HR 0.216 (95% CI, 0.131-0.357; p < 0.0001), demonstrating a reduction in the risk of disease progression or death for I+V of approximately 78% compared to C+O. vs. 11.4%) (p < 0.0001). Chicago, IL.:

Medicine 52

Medicine Production FDA Approval Trials 52

Pfizer

NOVEMBER 23, 2022

One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. PAXLOVID is generally administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice-daily for five days.

Licensing 40

Licensing Licensing Drugs Manufacturing 40